REGENXBIO Faces Shareholder Scrutiny Over Alleged Misstatements on RGX-111 Trial — Johnson Fistel, PLLP

Event summary

Johnson Fistel, PLLP is investigating claims on behalf of long-term REGENXBIO shareholders over alleged breaches of fiduciary duty by officers and directors.
A federal securities class action complaint alleges REGENXBIO misled investors about safety risks in its RGX-111 Phase I/II clinical trial.
The FDA placed RGX-111 on clinical hold in January 2026 after a participant developed a central nervous system tumor, causing REGNX stock to drop ~17.8%.
Shareholders who held REGNX shares continuously since before February 9, 2022, may seek corporate governance reforms and financial restitution.

The big picture

This investigation highlights the risks of overstating clinical trial success in biotech, particularly in gene therapy, where safety concerns can trigger regulatory actions. The case underscores the importance of transparency in disclosing adverse events, as even a single incident can derail development timelines and erode market value. REGENXBIO's ability to navigate this challenge will be critical for its long-term viability in a competitive therapeutic landscape.

What we're watching

Regulatory Headwinds: How the FDA's clinical hold on RGX-111 will impact REGENXBIO's pipeline and investor confidence.
Governance Dynamics: Whether this legal action will lead to leadership changes or operational reforms at REGENXBIO.
Execution Risk: The pace at which REGENXBIO can address safety concerns and regain regulatory approval for RGX-111.